HIV Vaccine Awareness Day at the AIDS Community Health Initiative Enroute to a Vaccine Effort (Project ACHIEVE), 18 May 2005

<p>(Photo: Project ACHIEVE)</p

Cumulative hazard estimate for virological failure.

<p>Cumulative hazard estimate for virological failure.</p

Associations between baseline characteristics and time to virological failure.

<p>*per category; EFV, efavirenz; NVP, nevirapine.</p><p>schoenfelds p = 0.12.</p

Additional file 1: of Mortality along the continuum of HIV care in Rwanda: a model-based analysis

Section S1. Additional Model Schematic, Description, and Parameters. Section S2. Model Calibration Figures. Section S3. Changing Mortality Distribution with Continuum Improvements. Section S4: Projected Prevalence Trends with Continuum Improvements. (DOCX 12869 kb

Additional file 1: of Prolactin-related adverse events and change in prolactin levels in pediatric patients given antipsychotics for schizophrenia and schizophrenia spectrum disorders: A systematic review

Figure S1. Evaluation of RCTs with the Cochrane risk of bias assessment. (PDF 267 kb

Additional file 1: Figure S1. of Risk of medication overuse headache across classes of treatments for acute migraine

Flow diagram for study selection. Table S1 List of studies excluded after full text review and accompanying reason for exclusion. (DOCX 113 kb

Additional file 1: of Statin use and all-cause mortality in people living with HIV: a systematic review and meta-analysis

Appendix S1. Medline Search Strategy. Appendix S2. Risk bias assessment. Appendix S3. PRISMA checklist. Table S1. Risk-of-bias assessment of included studies. Table S2. Estimated pooled HRs from the sensitivity analyses. (DOCX 41 kb

Summary of Considerations for Reporting and Interpretation of Results.

<p>Summary of Considerations for Reporting and Interpretation of Results.</p

Summary of Included Studies.

<p>Summary of Included Studies.</p

Summary of Considerations for Methodologic Reporting.

<p>Summary of Considerations for Methodologic Reporting.</p